In a preclinical house dust mite (HDM) mouse model of airway inflammation, itepekimab’s blockade of IL-33 significantly attenuated lung tissue injury and reduced inflammatory cell infiltration, supporting its potential to disrupt epithelial-driven inflammatory pathways in respiratory diseases [177]. Here, IL33 is linked to respiratory system disorder.